First Trust Advisors
PTGX icon

First Trust Advisors’s Protagonist Therapeutics PTGX Stock Holding History

First Trust Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.73M Sell
54,865
-32,993
-38% -$3.45M ﹤0.01% 1406
2026
Q1 		$9.26M Buy
87,858
+41,404
+89% +$3.67M 0.01% 1135
2025
Q4 		$4.06M Sell
46,454
-16,270
-26% -$1.33M ﹤0.01% 1517
2025
Q3 		$4.17M Sell
62,724
-51,183
-45% -$2.91M ﹤0.01% 1472
2025
Q2 		$6.3M Buy
113,907
+32,221
+39% +$1.55M 0.01% 1258
2025
Q1 		$3.95M Sell
81,686
-59,265
-42% -$2.48M ﹤0.01% 1432
2024
Q4 		$5.44M Buy
140,951
+27
+0% +$1.18K ﹤0.01% 1315
2024
Q3 		$6.34M Buy
140,924
+9,114
+7% +$368K 0.01% 1218
2024
Q2 		$4.57M Buy
131,810
+71,147
+117% +$2.08M ﹤0.01% 1307
2024
Q1 		$1.75M Buy
+60,663
New +$1.65M ﹤0.01% 1791
2022
Q3 		– Sell
-14,328
Closed -$113K – 2583
2022
Q2 		$113K Sell
14,328
-27,444
-66% -$332K ﹤0.01% 2450
2022
Q1 		$989K Buy
+41,772
New +$1.18M ﹤0.01% 2047

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

First Trust Advisors's PTGX Position: Q2 2026 in Review

First Trust Advisors reduced its Protagonist Therapeutics (PTGX) stake by 38% in Q2 2026, selling an estimated $3.45M and leaving 54,865 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

First Trust Advisors first reported a position in PTGX in Q1 2022 and has held it in 12 quarters since. The position peaked at $9.26M in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • First Trust Advisors held 54,865 shares of Protagonist Therapeutics worth $6.73M as of Q2 2026.
  • First Trust Advisors sold 32,993 Protagonist Therapeutics shares in Q2 2026, an estimated $3.45M.
  • Protagonist Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1406 holding.
  • First Trust Advisors first reported a position in Protagonist Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • First Trust Advisors's Protagonist Therapeutics position peaked at $9.26M in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.